The change comes a few weeks after the SEC ended its own “no-deny” policy.
Litigation
The judgment sends a powerful message about the limits of deceit in heavily negotiated M&A transactions and the high threshold for these types of claims.
What the ECJ's landmark ruling on defective products liability means for life sciences manufacturers
This article covers the expanded litigation risk, the steps life science companies should take to reinforce their product safety, and risk‑management governance.
Managing escalating technology litigation risk.
The judgment raises the question of whether there should be legislation to make a conversion-like cause of action apply to cryptocurrency.
The move signals an impending reboot of an often-criticized system.
How privilege claims should be managed when AI is involved.
Proactive steps companies in the healthcare sector (or those that insure or invest in those businesses) should take now.